期刊文献+

蛋白类药物缓释系统在眼部应用的研究进展 被引量:1

原文传递
导出
摘要 蛋白类药物的共同特点是药效高、生物半衰期短。蛋白组学的最新研究进展,特别关注其制剂技术。生物大分子类药物,尤其是多肽和蛋白质类,这些药物的缓释微球有很多优点,包括构象稳定,保留生物活性,保护化学和酶促降解,控制药物释放率,减少免疫毒性与其他生物效应。蛋白类药物的眼部应用,因其眼内通透性差,通常采用玻璃体腔注射。但由于游离药物生物半衰期短,如要保持有效的血药浓度需频繁注射。但频繁注射会引起并发症的增加。理想的给药方式是在玻璃体内注射长效缓释的给药系统,既降低药物在眼内的毒性,又可延长治疗时间。
出处 《中国实用眼科杂志》 2016年第8期785-788,共4页 Chinese Journal of Practical Ophthalmology
基金 国家重大新药创制专项课题(2014ZX09303301)
  • 相关文献

参考文献29

  • 1Prajapati V D, Jani G K and Kapadia J R, Current knowledge on biodegradable microspheres in drug delivery [J]. Expert Opin Drug Deliv, 2015, 12 (8) : 283 - 299.D01: 10.1517/ 17425247.2015.1015985.
  • 2刘丹岩,马景学,曹德英,王建欣,刘建宗,吕兰存.苦参碱聚乳酸微球的缓释性和玻璃体腔注射的安全性研究[J].眼科研究,2010,28(1):34-38. 被引量:14
  • 3Kim H, Csaky K G, Nanoparticle-integrin antagonist CI6Y pep- tide treatment of choroidal neovascularization in rats[J]. J Con- trol Release, 2010, 142 (2) : 286 - 293.
  • 4荣先芳,莫晓芬,任甜甜,袁伟恩,王艳,王鑫.促红细胞生成素缓释微球玻璃体腔注射对视网膜神经节细胞的保护作用[J].中华眼视光学与视觉科学杂志,2010,12(4):276-280. 被引量:3
  • 5Checa-Casalengua P,Jiang C,Bravo-Osuna I,et al. Retinal gan- glion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencap- sulation procedure I J]. J Control Release, 2011, 156(1):92-100. D O I : l 0.1016/j .jconrel.2011.06.023.
  • 6Li F,Hurley B, Liu Y,et al. Controlled release of bevacizumab through nanospheres for extended treatment of age-related macu- lar degeneration [J]. Open Ophthalmol J, 2012, 6: 54-58.
  • 7Xie B,Jin L, Luo Z,et al. An injectable thermosensitive poly-meric hydrogel for sustained release of Avastin(R) to treat pos- terior segment disease[J]. Int J Pharm,2015,490(1-2):375-383.
  • 8Robinson R,Viviano S R,Criseione J M,et al. Nanospheres de- livering the EGFR TKI AG1478 promote optic nerve regenera- tion: the role of size for intraocular drug delivery[J]. ACS Na- no, 2011,5 ( 6 ) : 4392 -4400. D OI : 10.1021/nn 103146p.
  • 9Souza M C, Fialho S L, Souza P A, et at. Tacrolimus-loaded PLGA implants:in vivo release and ocular toxieity[J]. Curr Eye Res,2014,39(l) :99-102.DOh 10.3109/02713683.2013.819927.
  • 10Backes S, Witt M.U, Roeben E, et at. Loading of PNIPAM Based Mierogels with CoFeO Nanopartieles and Their Magnetic Response in Bulk and at Surfaces[J]. J Phys Chem B,2015, 119(36) : 12129-12137.

二级参考文献11

  • 1金玉,张宏文.苦参碱及氧化苦参碱的抗纤维化作用研究进展[J].中国中西医结合肾病杂志,2004,5(8):493-494. 被引量:13
  • 2Sobaci G, Mutliu FM Vaver A,et al. Deadly weapon-related open-globe injuries:outcome assessment by lhe ocular trauma classification system [ J]. Am J Ophthalmol,2000,129:43 - 47.
  • 3Asaria RH, Charteris DG. Proliferative vitreoretinopathy : developments in pathogenesis and treatment[ J]. Compr Ophthalmol Update,2006,7: 179 - 185.
  • 4Acharya N, Young L. Sustained release drug implants for the treatment of intraocular disease[ J]. Int Ophthalmol Clin ,2004,44: 33 - 39.
  • 5Ciulla TA, Walker JD, Fong DS, et al. Corticosteroids in posterior segment disease : an update on new delivery systems and new indications [ J ]. Curr Opin Ophthalmo1,2004,15 : 211 - 220.
  • 6Berger AS, Cheng CK, Pearson PA, et al. Intravitreal sustained release corticosteroid-5-fluorouracil conjugate in the treatment of experimental proliferative vitreoretinopathy [ J ]. Invest Ophthalmol Vis Sci, 1996,37: 2318 -2325.
  • 7Herrero-Vanrell R, Refojo MF. Biodegradable microspheres for vitreoretinal drug delivery[J]. Adv Drug Deliv Rev,2001,52: 5- 16.
  • 8Li JK, Wang N, Wu XS. A novel biodegradable system based on gelatin nanoparticles and pep tide drug delivery [ J ]. J Pharm Sci, 1997,86 : 891 - 894.
  • 9郑马庆,潘伟娜,朱延勤.苦参碱滴眼液对家兔实验性眼炎的药效学研究[J].中药新药与临床药理,2003,14(2):109-111. 被引量:12
  • 10刘梅,刘雪英,程建峰.苦参碱的药理研究进展[J].中国中药杂志,2003,28(9):801-804. 被引量:216

共引文献15

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部